BridgeBio Pharma, Inc.
BBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$182,743 | -$183,758 | -$169,608 | -$267,389 |
| Dep. & Amort. | $1,398 | $1,317 | $1,284 | $1,367 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $37,241 | $25,882 | $30,127 |
| Change in WC | -$3,931 | $19,422 | -$116,166 | $12,945 |
| Other Non-Cash | $75,702 | $45,097 | $59,373 | $27,624 |
| Operating Cash Flow | -$109,574 | -$80,681 | -$199,235 | -$195,326 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,870 | -$594 | -$1,595 | -$47 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$2,968 | -$7,908 | $0 | $0 |
| Inv. Sales/Matur. | $8,000 | $0 | $0 | $0 |
| Other Inv. Act. | $2,302 | -$4,500 | $0 | -$3,190 |
| Investing Cash Flow | $4,464 | -$13,002 | -$1,595 | -$3,237 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$5,889 | $300,000 | $116,000 | $500,000 |
| Stock Issued | $8,020 | $0 | $0 | $0 |
| Stock Repurch. | $0 | -$1,995 | -$50,052 | -$1,404 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$3,025 | $4,036 | -$5,620 | -$24,665 |
| Financing Cash Flow | -$894 | $302,041 | $60,328 | $473,931 |
| Forex Effect | -$321 | $0 | $0 | $0 |
| Net Chg. in Cash | -$106,325 | $208,358 | -$140,502 | $275,368 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $749,402 | $542,742 | $683,244 | $407,876 |
| End Cash | $643,077 | $751,100 | $542,742 | $683,244 |
| Free Cash Flow | -$110,044 | -$85,775 | -$200,830 | -$198,563 |